Interleukin-2 immunoconjugate, cd40 agonist, and optionally pd-1 axis binding antagonist for use in methods of treating cancer

An immunoconjugate, PD-1 technology, applied in the field of interleukin-2 immunoconjugates, CD40 agonists, and optionally PD-1 axis binding antagonists for use in the treatment of cancer, can address advanced cancer patients with poor prognosis

Pending Publication Date: 2019-11-26
F HOFFMANN LA ROCHE & CO AG
View PDF73 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite advances in treatment options, prognosis for patients with advanced cancer remains poor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Interleukin-2 immunoconjugate, cd40 agonist, and optionally pd-1 axis binding antagonist for use in methods of treating cancer
  • Interleukin-2 immunoconjugate, cd40 agonist, and optionally pd-1 axis binding antagonist for use in methods of treating cancer
  • Interleukin-2 immunoconjugate, cd40 agonist, and optionally pd-1 axis binding antagonist for use in methods of treating cancer

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0079] The term "pharmaceutical composition" refers to a preparation which is in a form which permits the biological activity of the active ingredients to be effective and which is free of additional ingredients which are unacceptably toxic to a subject to whom the formulation will be administered. Preferably, such compositions are sterile.

[0080] "Pharmaceutically acceptable carrier" refers to ingredients other than the active ingredient in the pharmaceutical composition that are non-toxic to the subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers or preservatives.

[0081] As used herein, the term "treatment / treatment" refers to a clinical intervention designed to alter the natural course of a treated / treated individual or cell during the course of a clinical pathology. Desired effects of treatment / treatment include decreased rate of disease progression, amelioration or palliation of disease state, and regression...

Embodiment 1

[0444] Example 1: In vivo efficacy of FAP-targeted IL2v immunoconjugates alone and in combination with anti-CD40 mAbs and anti-PD-L1 mAbs in a mouse tumor cell line syngeneic model

[0445] FAP-targeted IL2v immunoconjugates alone and in combination with CD40 mAb and PD-L1 mAb were tested for their antitumor efficacy in a syngeneic mouse model.

[0446] Panc02-Fluc isogenic model of pancreas

[0447] The murine surrogate FAP-targeting FAP-IL2v immunoconjugate was tested in the mouse pancreatic Panc02-Fluc transfectant cell line injected intrapancreatically into Black 6 mice.

[0448] Panc02-H7 cells (pancreatic carcinoma in mice) were originally obtained from MD Anderson Cancer Center (Texas, USA) and deposited at the Roche-Glycart internal cell bank after expansion. The Panc02-H7-Fluc cell line was generated in-house by calcium transfection and subcloning techniques. Panc02-H7-Fluc was cultured in RPMI medium containing 10% FCS (Sigma), 500 μg / ml hygromycin and 1% Glutama...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides compositions and methods for treating cancer, the method comprising administering an IL-2 immunoconjugate, a CD40 agonist and optionally a PD-axis binding antagonist.

Description

[0001] field of invention [0002] The present invention relates to methods of treating cancer by administering an IL-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist. [0003] Background of the invention [0004] Cancer is one of the leading causes of death worldwide. Despite advances in treatment options, the prognosis for patients with advanced cancer remains poor. Therefore, there is a persistent and urgent medical need for optimal therapies that prolong the survival of cancer patients without causing unacceptable toxicity. [0005] Recent results from clinical trials have shown that immunotherapies, such as immune checkpoint inhibitors, can prolong overall survival and elicit durable responses in cancer patients. Despite these promising results, current immune-based therapies are only effective in a subset of patients, and combinatorial strategies are needed to improve therapeutic benefit. [0006] Interleukin-2 (IL-2), also known as T-ce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395C07K16/28C07K16/40C07K14/55A61K47/62A61K47/68A61P35/00
CPCA61K38/2013A61K39/3955C07K14/55C07K16/2827C07K16/2878C07K16/40A61K2039/507C07K2317/52C07K2317/73C07K2317/75C07K2317/76A61K47/6813A61K45/06A61K47/6851A61K47/6853A61P35/00A61K2300/00A61K39/39558A61K2039/505A61K47/6871C07K16/3007C07K2317/526C07K2317/565C07K2317/732
Inventor C.克雷恩V.G.尼科里尼P·乌马纳
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap